A combination of the GLP-1 peptide semaglutide and bariatric surgery significantly reduced BMI and improved quality of life in a teenager with juvenile Huntington disease and severe obesity.
BMI 44 → 33 kg/m²Combined semaglutide treatment and bariatric surgery achieved a 25% BMI reduction in a teenager with juvenile Huntington disease over approximately 9 months.
What the researchers found
A 17-year-old male with juvenile Huntington disease and severe obesity (BMI 44 kg/m²) was treated with semaglutide starting at 0.25 mg weekly, titrated to 1 mg. After 3 months on semaglutide, his BMI decreased by 7% to 40 kg/m². He then underwent laparoscopic sleeve gastrectomy at age 18. Six months postoperatively, his BMI dropped to 33 kg/m², liver enzymes improved, obstructive sleep apnea resolved, and he reported improved physical activity and quality of life.
Why it matters
This case demonstrates that GLP-1 receptor agonists like semaglutide can be safely used as part of a multimodal obesity treatment approach even in patients with progressive neurodegenerative conditions. It raises important ethical questions about prioritizing quality of life in patients with limited life expectancy and shows that aggressive obesity management can yield meaningful benefits in complex pediatric cases.
The numbers in context
n=1 · BMI 44 → 40 kg/m² (3 months semaglutide) · BMI 40 → 33 kg/m² (6 months post-surgery) · semaglutide 0.25–1 mg weekly · 7% BMI reduction on semaglutide alone
How the study worked
This is a single case report describing the management of a 17-year-old male with juvenile Huntington disease and severe obesity. Treatment included semaglutide titrated from 0.25 mg to 1 mg weekly, followed by laparoscopic sleeve gastrectomy. Outcomes were tracked over 6 months postoperatively, measuring BMI, liver enzymes, sleep apnea status, and quality of life. Ethics consultation and shared decision-making with the family were integral to the treatment plan.
Who was studied
17-year-old Hispanic male with juvenile Huntington disease and severe obesity (BMI 44 kg/m²)
What this study cannot tell us
As a single case report, these results cannot be generalized. The long-term outcomes of bariatric surgery and semaglutide in the context of progressive Huntington disease neurodegeneration are unknown. The follow-up period of 6 months post-surgery is relatively short. The relative contributions of semaglutide versus surgery to the overall outcome are difficult to separate.
How to read the evidence
This is a single case report, which represents the lowest level of clinical evidence. While it provides valuable real-world insight into managing a rare and complex clinical scenario, the findings cannot be generalized without larger studies.
When this study was published
Published in 2025, this is a very recent case report reflecting current clinical practice with semaglutide in complex pediatric obesity cases.
The bigger picture
This case sits at the intersection of two growing fields: GLP-1 peptide therapeutics for obesity and the ethical management of complex medical conditions in youth. As semaglutide and similar peptide drugs become more widely available, cases like this help define how they can be applied in challenging patient populations where traditional approaches may not be sufficient or appropriate.
Questions still open
- How will semaglutide's effects on appetite and weight interact with the progressive neurodegeneration and eventual weight loss seen in advanced Huntington disease?
- Could GLP-1 receptor agonists provide neuroprotective benefits in addition to weight management in Huntington disease patients?
- What ethical frameworks should guide obesity intervention decisions in youth with limited life expectancy from neurodegenerative conditions?
Common questions
What is semaglutide and how does it relate to peptides?
Why was this case ethically complex?
Read the original research
Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.
Journal of medical case reports, 19(1), 523
Citation
Vidmar, Alaina P; Martin, Matthew J; Abel, Stuart; Kim, Aimee G; Muñoz, Cynthia E; Weitzner, Madeleine; Derrington, Sabrina F; Samakar, Kamran. (2025). Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.. Journal of medical case reports, 19(1), 523. https://doi.org/10.1186/s13256-025-05615-2